New triple inhaler aims to tame tough asthma
NCT ID NCT07666490
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This study tests whether a triple-combination inhaler (containing an anti-inflammatory, a long-acting bronchodilator, and another bronchodilator) works better than a standard double-combination inhaler for people whose asthma is not well controlled. About 644 adults with asthma will use one of the two inhalers twice daily for 12 months. The main goal is to see if the triple inhaler improves asthma control scores and reduces flare-ups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Beclometasone, formoterol fumarate, and glycopyrronium bromide (Trimbow) triple inhaler
What this could lead to
If successful, this could show that a triple inhaler controls asthma better than a double inhaler for people whose asthma is not well managed.
What could go wrong
This is a phase 4 trial comparing existing drugs, so no major breakthrough is expected. The study is not yet recruiting, and results may show only a small benefit or no difference.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••